Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir + ribavirin for chronic hepatitis C with cirrhosis and portal hypertension
2012-002457-29Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatitis C virus infection comparing Sofosbuvir + ribavirin treatment arm with Observational arm with SVR12 assessed during observation (2 arms). Primary endpoints: SVR12 and SVR12 during observational period for Arm 2. Started Oct 2012; status: completed.
02
Drugs
sofosbuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2012-002457-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002457-29.